Business Context and Reporting Period
Company: Pluristem Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2011
Event Date: August 2, 2011 (Agreement Effective Date)
Business Context: The registrant's wholly owned Israeli subsidiary, Pluristem Ltd., entered into an Exclusive License Agreement with United Therapeutics Corporation. The agreement covers the development and commercialization of a cell-based product using Pluristem's PLacental eXpanded cells for the treatment of Pulmonary Hypertension.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Regulatory Approval: On July 27, 2011, Pluristem obtained the required consent from the Office of Chief Scientist in Israel regarding the Exclusive License Agreement.
- Agreement Effectiveness: Following the regulatory consent, the Exclusive License Agreement with United Therapeutics Corporation became effective on August 2, 2011.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the successful completion of a regulatory prerequisite (Israeli Office of Chief Scientist consent) that was required within 7 days of the initial agreement signing on June 19, 2011, to finalize the partnership with United Therapeutics Corporation.
Risks and Contingencies: The filing does not explicitly list new risks or contingencies beyond the prior requirement for regulatory consent, which has now been satisfied.
Investor Verification Checklist
- Verify the terms of the Exclusive License Agreement with United Therapeutics Corporation filed on June 20, 2011.
- Confirm the scope of the PLacental eXpanded cells technology licensed for Pulmonary Hypertension treatment.
- Monitor future filings for milestones related to the development and commercialization phases outlined in the agreement.